{"abstract":"The National Institute of Mental Health (NIMH), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Repurposed Therapeutics, Inc. (\"Repurposed Therapeutics\") located in Tampa, Florida, to practice the inventions embodied in the patent application listed in the Supplementary Information section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2019/05/03/2019-09099.html","cfr_references":[],"citation":"84 FR 19090","comment_url":null,"comments_close_on":"2019-05-20","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIMH Technology Transfer Office May 20, 2019 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2019-09099","effective_on":null,"end_page":19091,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2019/05/03/2019-09099.xml","html_url":"https://www.federalregister.gov/documents/2019/05/03/2019-09099/prospective-grant-of-exclusive-patent-license-scopolamine-therapeutics-for-depression-and-bipolar","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2019-09099?publication_date=2019-05-03","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2019-05-03/2019-09099/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":201,"last_updated":"2026-10-23 22:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2019-05-03/pdf/2019-09099.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2019-09099.pdf?1556801125","publication_date":"2019-05-03","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2019/05/03/2019-09099.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T19:20:02Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":19090,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Scopolamine Therapeutics for Depression and Bipolar Disorder","toc_doc":"Scopolamine Therapeutics for Depression and Bipolar Disorder","toc_subject":"Prospective Grant of Exclusive Patent License:","topics":[],"type":"Notice","volume":84}